Skip to main content
OpenTrials

Clinical trial condition

Poorly Differentiated Thyroid Gland Carcinoma

Explore clinical trials studying Poorly Differentiated Thyroid Gland Carcinoma. Study availability and eligibility vary by location and protocol.

10 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Poorly Differentiated Thyroid Gland Carcinoma trial results

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT02973997

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +38 more
Locations
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

NCT02393690

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Hoag Memorial Hospital Newport Beach, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View Trial Details
Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

NCT01811212

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +28 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT03914300

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +20 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
View all 33 locations
View Trial Details
Active, Not Recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT04544111

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details

Related conditions